Related Experiment Videos
[Drug therapy of atrioventricular tachycardia]
1Abteilung Innere Medizin III, Medizinische Universitätsklinik, Tübingen.
Insights
Antiarrhythmic drugs effectively treat junctional and AV-reentry tachycardias. Drug choice depends on targeting specific pathways and considering side effects and pharmacokinetics.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Junctional and AV-reentry tachycardias are common arrhythmias.
- Understanding the electrophysiological effects of antiarrhythmic drugs is crucial for effective treatment.
Purpose:
- To review the suitability of different antiarrhythmic drug classes for treating junctional and AV-reentry tachycardias.
- To elucidate the mechanisms by which various antiarrhythmic drugs affect cardiac conduction and refractoriness.
Summary:
- All antiarrhythmic drug classes can treat junctional and AV-reentry tachycardias.
- Beta-blockers, calcium antagonists, and digitalis primarily affect AV nodal conductivity.
- Class-1 antiarrhythmic drugs slow conduction in accessory pathways, with subclass 1c agents impacting fast pathways in dual AV-node conduction.
- Class-3 drugs prolong refractoriness throughout the heart, preventing re-entry in AV nodal tachycardias and WPW syndrome.
Impact:
- Guides clinical decisions for antiarrhythmic drug selection.
- Highlights the importance of considering drug side effects and pharmacokinetics in treatment.
- Provides a comprehensive overview of antiarrhythmic drug mechanisms in specific tachyarrhythmias.
Abstract:
All types of antiarrhythmic drugs are suitable for the treatment of junctional and AV-reentry Tachycardias. Betablocker, calcium antagonist and digitalis are mainly influencing the conductivity in the AV node, leaving other structures unaltered. In contrast, class-antiarrhythmic drugs slow conduction and prolong the refractor effect in the accessory pathway. In addition, drugs of subclass 1c can influence especially the 'fast' pathway in dual AV-node conduction. Class-3 drugs prolong refractoring in all compartments of the heart by preventing re-entry in both, AV nodal tachycardias and AV re-entry in the WPW syndrome. The clinical indication for one of these drugs is mainly influenced by the potential side-effects and by pharmacokinetic considerations.